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Abstract
Background: The S31N amantadine-resistance mutation in the influenza A M2 sequence currently occurs more
frequently in nature than the S31 wild type. Overcoming the resistance of the S31N mutation is the primary focus
of M2 researchers who aim to develop novel antiviral therapies. Recent studies have noted a possible rise in
frequency of the V27A/S31N double amantadine-resistance mutation in recent years. The purpose of this study is
to investigate this recent rise in frequency of the double mutation and any possible bias of the other mutations
toward co-occurrence with S31N or S31 strains.
Results: The primary dataset used for this study was comprised of 24,152 influenza A M2 channel sequences
which were downloaded from UniProt. There is an increased frequency for the S31N/V27A dual AR mutation in
recent years, especially in swine. A test for difference in two proportions indicates that the V27A mutation is
co-occurring with S31N more often than expected (p-value < 0.001) when considering individual amino acid
frequencies. At the same time, the different propensities for the V27A as compared to the V27T dual mutant may
reflect differences in viral fitness or protein energetics, and this information could be exploited to focus drug
development so as to reduce further drug insensitivity.
Conclusions: The development of the S31N/V27A variant in the Midwestern US swine may be a harbinger of
novel human strain development. V27A/S31N is a possible path forward for the evolution of M2 which may
convey a new level of drug resistance and should receive attention in drug design.
Background
The amantadine-resistance (AR) S31N influenza A M2
channel mutation is currently the most prevalent form of
the M gene in human isolates in both H1N1 [1] and
H3N2 [2] subtypes. Overcoming the AR of the S31N
mutation is the primary focus of M2 channel researchers
[3,4]. In addition to S31N, previous studies have shown
that a number of mutations near the drug-binding site
can lead to AR, including V27A, V27T, V27S, A30T,
G34E and L26F [5]. It is in the interest of all researchers
who are investigating the M2 channel to not only over-
come S31N AR strains, but also to predict the rise in fre-
quency of other AR mutations, including double AR
mutations. The presence of double AR mutant strains
was noticed in small frequencies in 2009 [6,7], and was
later confirmed in 2012 by Garcia et al., who made note
of a possible rise in frequency since 2009 [8]. One study
conducted by Abed et al. helped to characterize the
V27A/S31N mutation. Through a reverse genetics
approach, these researchers produced a V27A/S31N
double mutant (among other AR mutations) from the
A/WSN/33 strain. They then infected 16 mice and
recorded that “all mutants were at least as virulent as the
WT in experimentally infected mice, with the highest
mortality rate being obtained with the recombinant
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harboring a double V27A/S31N mutation [9].” Interest-
ingly, however, the study also reported that the V27A/
S31N double mutant is less resistant to amantadine
(although still considered amantadine resistant on the
whole) than either of the S31N or V27A mutations, pro-
viding some evidence against a synergistic effect of these
two mutations on amantadine sensitivity.
It became clear throughout the course of this study
that the V27A/S31N double mutation is rising in pro-
portion primarily in the swine population. This raises
the question of the potential for virus transmission from
swine to humans. Past research has shown that swine to
human transmission of the influenza A virus is possible
and occurs regularly. In recent years more work has
been done to more precisely trace these interspecies
transmissions of the virus, and to then determine the
likelihood of human to human viral transmission [10].
The swine population, termed by others as a “mixing
vessel” for influenza viruses, has generally been consid-
ered the last step taken by novel influenza viruses prior
to complete transmission to the human species [11].
These studies further prompt researchers to consider
M2 evolutionary trends even in non-human species
when designing and testing potential drugs.
These observations prompted the researchers of this
study to better characterize this recent rise in dual AR
mutation frequency. In the past decade, sequencing
technology has improved dramatically and produced a
wealth of influenza A M2 channel sequence data that
enables researchers to track and predict the evolution of
the virus with great precision [6]. This paper reports the
utilization of a Z test for difference in proportions to
characterize the frequencies of dual AR mutations using
M2 sequences from the UniProt database.
Methods
M2 sequence set preparation
28,042 influenza A M2 protein sequences with 97 total
amino acids were downloaded on August 28th, 2014
from the UniProt.org database (Additional file 1). This
initial set was first filtered by removing experimental
strain crosses, fragments, sequences with no given sub-
type, and otherwise poorly cataloged sequences, result-
ing in a set of 24,152 sequences
This initial set of all sequences was further divided
into 6 subsets, three divided by isolation year, pre-2000,
2000-2010 and post-2010; and three sets divided by host
organism: human, swine, and other. These subsets were
further reduced by including only one copy of each
unique sequence (to reduce heritance and resampling
biases) that occurred at least twice (to eliminate ero-
neous sequence determinations) in each sequence sub-
set. The results of applying these filters are given in
Table 1. This filtering technique allows for the same
unique sequence to be shared among sequence subsets
in the event that it occurs in more than one subset.
Each sequence subset was reduced by 95% on average,
with the greatest reduction being that of the human set,
an indication of especially high sequence repetition in
this subset. Filtering was performed using custom
python scripts. By analyzing only all unique sequences
with a minimum duplicate count of two, the sequence
subsets avoid two extremes in large-scale sequence ana-
lysis: analyzing all duplicates together which could
potentially lead to a very strong sampling bias, and ana-
lyzing only unique sequences which could give sequen-
cing errors much greater weight in the set. These
refined sequence subsets were the primary focus of sta-
tistical analysis in this study.
Amino acid frequency calculation
The frequency of occurrence of a given amino acid in a
sequence subset was calculated by dividing the count for





Here, fap is the frequency of occurrence of amino acid
a at position p, Nap is the count of sequences having
amino acid a at position p, and Nt is the number of
sequences in the subset.
Test for the difference in two proportions: Independence
from the identity of residue 31?
A test for the difference in two proportions was per-
formed for each subset on all non-residue 31 amino
acids, focusing primarily on the other amantadine-resis-
tance cites, that occurred in at least one unique
sequence to test for a significant difference in amino
Table 1. The effect of applying filters to sample on
overall sample size
Total Unique Unique N > 2 % Red.
All Sequences 24152 2530 1007 95.83%
Pre-2000 2396 475 184 92.32%
2000-2010 13753 1473 560 95.93%
Post-2010 8003 909 373 95.34%
Human 13315 783 310 97.67%
Swine 3288 742 277 91.58%
Other 7549 1103 453 94.00%
Six subsets of the total sequence set were constructed: three divided by date
of isolation (Pre-2000, 2000-2010, and Post-2010), and three divided by host
organism (human, swine, other). Two filters were applied to the unfiltered
sequence subsets (’Total’): the first filter including only unique strains
(’Unique’ column), and a second filter including only those unique strains that
occur at least twice in the unfiltered sequence set (’Unique n > 2’). The ‘%
Red.’ column refers to the reduction in set size that takes place between the
‘Total’ column and the ‘Unique n > 2’ column. A higher percent reduction is
an indication of high sequence repetition in the initial set.
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acid frequency in S31 and S31N strains (Additional file 2).



















Where Zap is the Z score of amino acid a at position
p (where p ≠ 31), Nap,S31 is the count of sequences in
which amino acid a at position p occurs simultaneously
with (WT), NS31 is the count of sequences in which
occurs, Nap ,S31N is the count of sequences in which
amino acid a at position p occurs simultaneously with,
NS31N is the count of sequences in which occurs, and Nt
is the total number of sequences in the sequence subset.
P-values were directly calculated from the Z scores
assuming Z to be normally distributed, to evaluate the
statistical significance of deviations from expected pro-
portions. Deviations from the expected proportions are
assumed, based on the reduction in heritance bias by
the filtering, to be an indication that the amino acids in
question are occurring preferentially with S31 or S31N
due to energetic/functional effects on the fitness of the
virus. A pseudo-Bonferonni corrected p-value threshold,
0.005, was applied to determine signficant deviations
from expected proportions, and less than 10 unique
occurences of a given amino acid was considered insuffi-
cient data to determine a bias toward S31 or S31N.
S31N, V27A, V27T mutation frequencies over time
To evaluate the advancement of the three most com-
mon AR mutations and correlations between residues
27 and 31 (which are spatial neighbors), the unfiltered
sequence sets representing strains collected from all
host organisms, only humans, swine, and all other hosts
were subdivided chronologically by decade of virus isola-
tion, starting with the decade beginning in 1930 and
ending with the decade beginning in 1990, and then by
year starting with 2000 and ending with 2012, and
finally sequences isolated between 2013 and the time
the sequences were downloaded (August 2014). These
sequences subdivided by year were then filtered to
unique sequences occurring at least twice in the unfil-
tered set, as described previously.
The frequency of the amino acids S31N, V27A and
V27T in each individual subset was calculated according
to equation 1.
Also, the proportion of S31N mutants occur simulta-









Where fdm is the frequency of double mutants within
the S31N sample, N27A/N31 is the count of sequences
that possess both a V27A and an S31N mutation, N27T/
N31 is the count of sequences which possess both a
V27T and an S31N mutation, and NN31 is the count of
sequences which possess an S31N mutation. 95% confi-
dence intervals of the frequencies were calculated for
each subset using a 1000x bootstrapping technique,
implemented using the boot package (v1.3-13) in R.
Each subset was resampled with replacement to produce
1000 subsets of equal size to the original, and the fre-
quencies of the amino acids of interest were calculated
for each to produce a distribution that was then ana-
lyzed by the boot.ci function to produce 95% confidence
intervals.
Results
General details of overall sequence set
The overall sample of 24,152 sequences was comprised
of strains collected from ~266 different organisms
(Additional file 2), which were grouped as human
(55.3%), swine (13.6%), and other organisms/sources
(31.1%). The sample was comprised of 82 different influ-
enza subtypes in total: 37.4% H1N1, 28.4% H3N2, 6.0%
H5N1, 3.9% H1N2, 3.8% H3N8, and 20.5% other sub-
types (Additional file 2). Approximately 887 different
locations are represented in the sample (Additional file
2), 530 of which are associated with two or more
sequences, and 54 are associated with 100 or more
sequences. The 54 most represented locations are asso-
ciated with 68% of all sequences. Of these (16,434
sequences), 65.72% were collected in North America,
12.24% in Asia, 8.95% in Europe, 8.25% in Southeast
Asia, 4.17% in South America, and 0.66% in Africa.
Amino acid frequencies indicate highly conserved regions
and evolutionary trends
In order to better understand general evolutionary trends
for the M2 protein, an amino acid frequency table was
generated for sequenced isolates dated 1933-2000 (pre-
2000), 2000-2010, and 2010-present, (Additional file 2).
Dominant sequences and deviations in the filtered subsets
(unique sequences occuring more than once) for these
three time periods are shown in Figure 1. The results indi-
cate the protein domains which are evolutionarily con-
served, as seen by a general lack of amino acid diversity in
specific regions. Residues 1-10 of the N-terminal domain
are highly conserved, as are several residues of the trans-
membrane domain (residues 22-49), especially His37
which forms the selectivity filter. In spite of considerable
sequence fluctuation within eras, the level and breadth of
diversity is very steady over the three different eras, indi-
cating a high level of functional/energetic requirements at
each position, consistent with the well-defined structure of
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the entire protein [12-14] and the numerous specific func-
tions of each domain in the protein [15-19]. Variations
that appear in more than 1% of the sequences are gener-
ally of the same side chain type and never exceed four in
number. Only at 18 positions (11, 13, 14, 15, 18, 20, 27,
28, 31, 43, 54, 55, 57, 77, 78 82, 89 and 93) do the domi-
nant residue frequencies drop below 75% occurrence fre-
quency in any of the three groups, and even these sites
generally have homologous substitutions. Only at positions
11, 14, 16, 18, 20, 28, 31, 55, 57, 82, 86, and 93 do any of
the variants from the dominant residue ever reach a fre-
quency >30%, and in all of these cases only a single substi-
tution is so common.
With regards to AR mutations, the dominant amino
acid at position 31 shifts from 71.6% serine (S) to 59.9%
asparagine (N) between the 2000-2010 and post-2010
sequence sets, as reported previously [1,2]. The AR
V27A mutation rises in prevalence from 1.1% to 7.8% of
unique sequences between sets 1 and 3. V27T follows a
similar trend to V27A, but with a yet lower frequency
(0.5%) than V27A in the pre-2010 sequence set, and a
yet higher frequency (8.8%) in the post-2010 sequence
set. V27S is a rare mutation, never appearing with a
frequency greater than 1%. L26F occurs with frequency
greater than 1% only in the pre-2000 and 2000-2010
sequence sets. A30T and G34E occur with <1% (or
never) in all three filtered sequence sets. Position 28 is
not a recognized AR site but has been recently found to
modulate the impact of residue 31 on drug blocking
(personal communication, David Fedida and Ian Tiet-
jen). It shows a shift in amino acid frequency across the
three sequence sets, with isoleucine (I) being the most
frequent amino acid in the pre-2000 sequence set, valine
(V) being the most frequent in the 2000-2010 sequence
set, and a reversion to isoleucine in the post-2010
sequence set.
In summary, AR mutations S31N, V27A, V27T, and
L26F all occur in significant numbers in at least one of
the three sequence sets. AR mutations V27S, A30T, and
G34E do not occur with significant frequency. In the
most recent period, the post-2010 sequence set, S31N,
V27A, and V27T are the only three AR mutants that
appear with significant frequency. No variation other
than N has appeared (>1%) in isolates at position 31.
V28I has increased and may cause further complications
for M2 researchers.
Figure 1 General evolutionary trends of the Influenza A M2 Channel over three epochs. Frequencies of each amino acid occuring in more
than 1% of strains are shown for the three epochs: previous century, past decade, and current decade. This table does not filter out specific host
organisms; they are all considered together. Colors are assigned according to amino acid frequency; if the percentage of occurrences for an
amino acid within the entire set is between two of the frequency cutoffs (specified in the legend below), it is assigned the color associated with
the lower cutoff.
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Test for difference in proportions indicates a significant
V27A/S31N double AR mutation bias
A test for difference in proportions was performed to
indicate whether each non-S31N AR mutation dispro-
portionately occurred in conjunction with S31 or S31N
for the six subgroups. In addition, the frequencies of
mutation from proline to leucine or histidine at position
10 were evaluated for the S31 and S31N groups as a
control due to the expected spatial separation of residue
10 from residue 31, and an assumed lack of functional
relations between them that might produce evolutionary
pressure.
Between the three epochal subsets, the apparent bias
of each of the non-31 AR mutations toward S31 or
S31N is shown in Table 2. Prior to year 2000, the
unique, replicable sequences with S31N were sparse
(NS31N = 12), so the statistics are not persuasive, but AR
mutations V27A, V27T, and appear disproportionately
in conjunction with the S31N AR mutation and no pre-
ference for S31 can be demonstrated. Between years
2000 and 2010, V27A appears with both S31 and S31N
strains, but V27T dominates with S31 strains. Following
2010, V27A heavily favors S31N, occurring in conjunc-
tion with S31N in 29 sequences, while never occurring
in conjunction with S31. V27T shows the opposite pat-
tern, occurring in conjunction with S31 a total of 33
times, and never with S31N. V28I appears in conjunc-
tion with S31N more often than expected.
To evaluate whether the results are robust, as opposed
to (for example) reflecting host species biases for certain
viral strains, the sequence set was divided into sets of
human, swine, and all other hosts rather than epochs
(Table 3). Among dual AR mutations, V27A/S31N is
most common in swine hosts. Human sequences seem
to be largely void of double mutations, as do the other
host sequences. However, the control mutation P10L
shows a disproportionate bias toward S31N possibly
indicating a strong heritance bias in the swine set.
In summary, in recent years the AR V27A mutation is
occurring in conjunction with S31N more frequently
than expected by chance, while V27T is occurring pri-
marily with S31. Both of these mutations are primarily
occurring in swine-host strains. Proline variants H and
L at the presumably nondiscriminatory position 10,
were insensitive (P > 0.005, with the pseudo-Bonferroni
correction) to the residue at position 31 in 5 of the 12
cases tested, but were sensitive in 1 of the 12 cases
tested, suggesting a possible heritance bias. (Data was
inadequate in 6). Therefore, it is not certain from this
test whether or not the bias that amino acids such as
V27A have toward S31N is due to a functional or ener-
getic advantage as opposed to heritance effects. Never-
theless, with the higher numbers of sequences
representing the V27A, V27T, and S31N mutations, it
seems likely that functional and/or energetic effects are
important and it is clear that the V27A/S31N dual AR
mutation is occurring more often than expected by
chance.
Table 2. Test for difference in proportion table for
sequence sets divided date of isolatiion
Pre-2000
Nt = 184, NS31 = 171, NS31N = 12
AA+S31 AA+S31N Favors P-value
10L 6 0 NA ID
10H 4 0 NA ID
26F 1 1 NA ID
27A 0 2 NA ID
27T 0 1 NA ID
27S 0 0 NA ID
27I 21 0 NA 0.1
28I 71 11 S31N <0.001
30T 0 0 NA ID
34E 0 0 NA ID
2000-2010
Nt = 560, NS31 = 401, NS31N = 157
AA+S31 AA+S31N Favors P-value
10L 31 9 NA 0.2
10H 13 7 NA 0.24
26F 2 5 NA ID
27A 11 7 NA 0.15
27T 8 0 NA ID
27S 2 0 NA ID
27I 69 4 S31 <0.001
28I 154 57 NA 0.32
30T 1 0 NA ID
34E 0 0 NA ID
2010-present
Nt = 373, NS31=151, NS31N = 222
AA+S31 AA+S31N Favors P-value
10L 8 13 NA 0.41
10H 8 8 NA 0.21
26F 0 3 NA ID
27A 0 29 S31N <0.001
27T 33 0 S31 <0.001
27S 0 0 NA ID
27I 33 4 S31 <0.001
28I 73 133 S31N <0.05
30T 0 0 NA ID
34E 0 0 NA ID
The amino acids of interest are included in the left column. The ‘AA+S31’
column is the count of amino acids in the left column that occur in
conjunction with S31 (WT). The ‘AA+S31N’ column is the count of amino acids
in the left column that occur in conjunction with S31N. The ‘Favors’ column
indicates the amino acid, S31 or S31N, with which the amino acid in the left
column occurs more often then expected, according the test for difference in
proportions. The ‘P-value’ column gives the p-value of each test for difference
in proportion. ID: insufficient data (<10 samples of the AA).
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Year by year frequency of S31N, V27T, and V27A
mutations shows distinct rise in double mutations
In order to better correlate and visualize the changes in
S31N, V27A (Figure 2), and V27T (Figure 3) mutation
frequencies with greater time resolution, the relative
frequency of each amino acid over time was calculated
as described in the methods section. In the 1930s and the
1940s, a higher frequency of S31N mutations (Figure 2,
top row of panels) is evident as a result of the heavy sam-
pling bias toward A/WSN/1933, a strain of great interest
to researchers due to its S31N mutation and the fact that
it was the first isolated influenza strain. The large 95%
confidence intervals indicate that the high number of
S31N mutations in this sample set is not significant due
to the small sample size. However, from year 2005 on
there is a steady increase in S31N mutation frequency
within all species considered together. In the human host
strains, the S31N mutation is present in 100% of
sequences from the year 2010 on. Somewhat unexpect-
edly, the S31N mutation is not quite as prevalent in the
swine subset, comprising ~80% of all swine sequences in
the most recent year. The S31N mutation has also
increased in frequency in other hosts but not to the same
extent as in human hosts or swine hosts, reaching ~40%
of all other host sequences in the most recent year.
V27A (Figure 2, 2nd row of panels) has increased in
frequency among swine in recent years, rising from 0%
in 2010 to ~30% in the most recent year. Earlier occur-
rences of the V27A mutation do not appear to be sig-
nificant according to the 95% confidence intervals.
Additionally, the V27A/S31N double AR mutation
(Figure 2, 3rd row of panels) is occurring more fre-
quently in recent years, with the V27A occurring in
~40% of S31N swine-host strains. The V27T mutation,
which was shown in the previous section to occur pri-
marily with S31 over S31N, has also increased steadily
in frequency among swine (Figure 3, first row of
panels), but in the most recent year it did decline in
frequency from ~26% to 15% of all swine strains. It
only occurs in significant numbers in the swine sample.
In contrast to V27A, the V27T mutation did not
increase significantly in frequency among S31N strains
(Figure 3, second row of panels, especially in the swine
column) as its overall frequency increased. This pro-
vides further evidence that there is a distinct bias for
the V27T AR mutation to occur in conjunction with
S31, and not with S31N. This analysis identifies a dis-
tinct correlation between positions 27 and 31.
Details of dual AR V27A/S31N mutants
A total of 553 double AR V27A/S31N M2 total
sequences were collected from swine (of which 29
sequences were unique and occurred at least twice). Of
the 553 V27A/S31N sequences, 135 were collected from
swine in Ohio, 80 from Iowa, 78 from Indiana, 75 from
North Carolina, 54 from Illinois, 27 from Minnesota, 15
from Korea, 13 from Nebraska, 10 from Kansas, and the
remaining 54 were shared among 27 other unique loca-
tions, primarily in the Midwestern United States. The
Table 3. Test for difference in proportion table for
sequence sets divided by host organism
Human
Nt = 313, NS31 = 151, NS31N = 161
AA+S31 AA+S31N Favors P-value
10L 1 2 NA ID
10H 1 3 NA ID
26F 2 2 NA ID
27A 5 6 NA 0.42
27T 0 1 NA ID
27S 0 0 NA ID
27I 3 2 NA ID
28I 11 74 S31N <0.001
30T 0 0 NA ID
34E 0 0 NA ID
Swine
Nt = 277, NS31 = 145, NS31N = 131
AA+S31 AA+S31N Favors P-value
10L 1 5 NA ID
10H 5 4 NA ID
26F 0 4 NA ID
27A 1 29 S31N <0.001
27T 38 0 S31 <0.001
27S 2 0 NA ID
27I 69 4 S31 <0.001
28I 6 111 S31N <0.001
30T 0 0 NA ID
34E 0 0 NA ID
Other Hosts
Nt = 539, NS31 = 447, NS31N = 91
AA+S31 AA+S31N Favors P-value
10L 48 18 S31N <0.01
10H 22 8 NA 0.21
26F 1 1 NA ID
27A 8 4 NA <0.001
27T 5 0 NA ID
27S 0 0 NA ID
27I 50 0 S31 <0.001
28I 274 22 S31 <0.001
30T 1 0 NA ID
34E 0 0 NA ID
The amino acids of interest are included in the left column. The ‘AA+S31’
column is the count of amino acids in the left column that occur in
conjunction with S31 (WT). The ‘AA+S31N’ column is the count of amino acids
in the left column that occur in conjunction with S31N. The ‘Favors’ column
indicates the amino acid, S31 or S31N, with which the amino acid in the left
column occurs more often then expected, according the test for difference in
proportions. The ‘P-value’ column gives the p-value of each test for difference
in proportion. ID: insufficient data (<10 samples of the AA).
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large sampling of swine from Ohio is due in part to an
active surveillance project being carried out by research-
ers at Ohio State University [10]. 532 of these strains
have been collected since 2009, and 284 were collected
in 2013 and 2014. 285 sequences belong to the H3N2
subtype, 148 belong to H1N2, 117 sequences belong to
H1N1, and 3 belong to H3N1.
Only 42 dual AR V27A/S31N sequences (total) have
been collected from human hosts. 10 of these sequences
belong to the A/Puerto Rico/8/1934 sequence, which
has been repeatedly sequenced. Of the remaining 32, 5
were collected in Indonesia, 4 in Australia, 3 in Iowa, 3
in Tennessee, 2 in Helsinki, and the remaining 15 were
collected from 13 other locations. 19 of the remaining
32 have been collected since 2009, and 4 have been col-
lected in 2013 and 2014.
Thus the V27A/S31N dual-AR M2 sequence is very
common in Midwestern swine, and although it appears
in human hosts at only small relative frequencies, it is
broadspread geographically.
Conclusions
The results of this study should function as a starting
point for further investigation into the potential risk
presented by double AR mutations. V27A/S31N double
AR strains are presenting themselves more frequently in
swine in recent years. Similarly, V27T appears more fre-
quently in swine than other species, but with S31. Even
upon further sample filtering to analyze only influenza
strains isolated from swine in the USA, the bias of the
V27A mutation toward S31N strains is still strongly sig-
nificant (p-value < 0.001), with no V27A/WT unique
Figure 2 V27A and S31N mutations over time. Frequencies of mutation appearances relative to the total number of sequences in the
subgroup (rows 1 and 2) or the total number of S31N mutants in the subgroup (row 3). Columns of panels are labelled according to the host
organism associated with each sequence subset. 95% confidence intervals are indicate the grey ribbon. Years are indicated both on the bottom
and the top of the figure.
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M2 sequences and 26 unique V27A/S31N M2 sequences
occurring in this subset. It is possible that the proton
transport properties of the M2 channel that depend on
luminal residues 27 and 31 co-vary, with the small
(methyl) side-chain of A27 allowing more space for
water and protons to enter and interact with the polar
N31 side chain, whereas the V27T mutation more subtly
enhances water entry through polarity in the side chains,
somehow more consonant with the mild polarity of S31
side chains.
The possibility of a second viable amantadine resistant
mutation could further complicate the endeavors of
Influenza M2 channel researchers, potentially rendering
novel S31N blockers ineffective. Future anti-viral studies
should explore blocking effects in both S31N and
V27A/S31N mutants.
Additional material
Additional file 1: Raw Sequence Data. This is a fasta protein sequence
file. It contains the unfiltered M2 sequence data as it was originally
downloaded from the UniProt database.
Additional file 2: Supplementary Data. This is an Excel spreadsheet file
(.xlsb) The content of this file are as follows: Supplementary Table 1: A
table demonstrating the proportion of all non-human host organisms
from the original sample of 24,152 sequences. Supplementary Table 2: A
table demonstrating the proportion of the various subtypes from the
original sample of 24,152 sequences. Supplementary Table 3: A table
demonstrating the proportion of each strain collection location from the
original sample of 24,152 sequences. The top 55 locations are also
labeled by the region in which they reside, designated as follows: North
America (NA), Asia (AS), Southeast Asia (SEA), South America (SA), Africa
(AF), Europe (EU), and Australia (AU). Supplementary Table 4: This table
contains the results of the test for difference in proportion for each
amino acid that occurs at all 97 positions in all sequence subsets. The
“Sequence Set” column refers to the subset to which the amino acid and
subsequent data belong. There are 7 subsets represented, all of which
include only unique sequences that occur at least twice: All Sequences
(ALL), PRE-2000, 2000-2010, 2010-PRESENT, HUMAN, SWINE, OTHER
HOSTS. The next two columns include the amino acid of interest and its
position. The ‘Total’ column refers to the total sequence count in the
subset. Count S31 and Count S31N refer to the count of each of the two
amino acids in the subset. These numbers do not always add up to the
Total column, because there are a small number of sequences that have
an alternative mutation at position 31. Count AA+S31 and Count AA
+S31N refers to the count of sequences that contain both the amino
acid of interest and the S31 or S31N amino acids. The Z-score and p-
value columns demonstrate whether the proportions deviate significantly
from the expected distribution according to the pseudo-Bonferroni
corrected p-value of 0.005, represented by green highlighted cells. In the
event that the statistics indicate a significant bias toward either S31 or
S31N, the amino acid is shown in the ‘Favors’ column. ID: insufficient
data (<10 samples of the AA) NA: Not applicable, the amino acid
position only had one variant in the sample.
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